Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers

• Published in: Translational research : the journal of laboratory and clinical medicine Vol. 223; pp. 40 - 60
• Main Authors: Ozawa, Patricia Midori Murobushi, Jucoski, Tayana Schultz, Vieira, Evelyn, Carvalho, Tamyres Mingorance, Malheiros, Danielle, Ribeiro, Enilze Maria de Souza Fonseca
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2020
• Subjects: BC; cf-miRNAs; PR; EVs; OS; OPN; ER; c-miRNAs; AUC; CT; dPCR; ERBB2; CA15-3; PAI-1; EV-miRNAs; NGS; TNBC; RANTES/CCL5; RT-qPCR; CTCs; CEA; breast cancer; Circulating miRNAs; extracellular vesicles; cell-free miRNA; biomarker; liquid biopsy
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2020.04.002

Improvement of breast cancer (BC) patient's outcome is directly related to early detection. However, there is still a lack of reliable biomarkers for diagnosis, prognosis and, treatment follow up in BC, leading researchers to study the potential of liquid biopsy based on circulating microRNAs (c-miRNAs). These c-miRNAs can be cell-free or associated with extracellular vesicles (EVs), and have great advantages such as stability in biofluids, noninvasive accessibility compared to current techniques (core-biopsy and surgery), and expression associated with pathogenic conditions. Recently, a new promising field of EV-derived miRNAs (EV-miRNAs) as cancer biomarkers has emerged, receiving special attention due to their selective vesicle sorting which makes them accurate for disease detection. In this review, we discuss new findings about c-miRNA and their potential as biomarkers for BC diagnosis, prognosis, and therapy. Additionally, we address the impact of limitations associated with the standardization of analysis techniques and methods on the implementation of these biomarkers in the clinical setting.